Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Abstract Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTK...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2023-08-01
Sarja:	Journal of Hematology & Oncology
Aiheet:	BTK inhibitor resistance Mantle cell lymphoma CAR T cell therapies Bispecific antibodies Antibody–drug conjugates
Linkit:	https://doi.org/10.1186/s13045-023-01496-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!